Abstract
Preclinically, PARP inhibitors (PARPi) + TOP1 inhibitors have shown highly synergistic antitumour effects, but clinical development has been hampered by overlapping toxicities. Tumour-targeted delivery of a TOP1 inhibitor may reduce systemic toxicity of the combination; thus, we evaluated the PARPi rucaparib + SG, an antibody-drug conjugate composed of an anti-Trop2 antibody coupled to the active metabolite of irinotecan (SN-38) via a unique hydrolyzable linker.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
